Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[knuts4oe]

MineAllMine

I have long assumed that Drs Mullan and Crawford, and Robert Roskamp would love to have anatabine as part of the Roskamp Institute effort, if only because of all the work they have put into developing the science surrounding it.

Attached is a link to the list of drugs currently in trials to determine their potential impact on Alzheimer’s Disease. This year old list estimates the Nilvad trial completion in Dec. 2017, the Reg filing date in Dec. 2018, and the Launch Date in the 3rd Qtr. of 2019. Since they were off about 10 months on the trial completion date, I assume we can adjust their Launch Date 10 months earlier to the 4th Qtr of 2018.

http://www.usagainstalzheimers.org/sites/default/files/RA2_Pipeline_Report.pdf

As I expect that Archer Pharma will be announcing the trial results any day, week, or month now, and that those results will be favorable, Archer and Roskamp should receive a lot of media attention as the first one to impact AD in a significant way. Dr. Mullan then has the task of getting Nilvadipine approved for treating AD as soon as possible. One can only fantasize what the market demand will be, but it should be awesome!

That in turn sets up Rock Creek reapplying as a Delaware corporation, and merging as equals with Archer. Archer brings cash flow and a functioning pharma to the merger, and Rock Creek brings NOLs and a mighty patent position.

Seems like one could spin a mighty future for this fantasy tale!